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Each month, Chemistry & Biology Select highlights a selection of research reports from the recent
literature. These highlights are a snapshot of interesting research done across the field of chemical
biology. Our April 2015 selection includes reports on using DNA to control protein crystallization,
identification of the new posttranslational modification (spoiler alert: it’s polyphosphate), selectivity
profiles of BH3 mimics, and how the metabolic picture of pluripotent stem cells changes as they
start to differentiate.The double helix of DNA is probably the most
iconic image that biology has produced. DNA is
well known as a molecule that carries our
genetic code, but DNA is mightier than that,
and its remarkable chemical and mechanical
properties make a useful building material
for nanotechnology. Brodin et al. now use
DNA-DNA interactions to address a difficult
problem of guiding and controlling protein
crystallization.From Genes to Girders
DNA is an easily recognizable acronym for deoxyribonucleic acid that most
people associate with genes and genetics. What is less widely recognized is
that DNA is also an excellent nanoscale building material. Since the 1980s,
researchers have been exploring the use of DNA to make different 3D struc-
tures, and, more recently, nanomachines. DNA is a versatile building material
because of its ability to spontaneously organize into stable structures. This pro-
cess is driven by the base-pairing rules and it is programmable and controllable.
Unfortunately, the same is not true for the other prominent group of biomole-
cules—proteins. Although many proteins crystallize, interactions and forces
that guide the formation of crystal lattice are exceptionally complex, and the
rules that guide protein crystallization have yet to be formalized. In practical
terms, this means that it is very difficult to predict whether a protein will crystal-
lize and what crystal lattice it will assemble into.
Brodin et al. now use DNA-DNA interactions to guide protein crystallization
and show that DNA can guide the formation of desired crystal lattices. To illus-
trate how the method works, Brodin et al. use bovine catalase and Corynebac-
terium glutamicum catalase. First, they convert all surface-exposed amines to
azides, and then use Cu-free ‘‘click chemistry’’ to attach two different DNA
tags to the proteins. Here, each DNA tag consists of a double-stranded DNA
chain with a single-stranded sticky end sequence that is needed to achieve
complementarity-driven assembly. After confirming that the catalases retain
their structure and activity when conjugated to DNA, Brodin et al. combine proteins with complementary oligonucleotide
tags, allow the aggregation to take place, heat the aggregates to close to their melting point, and allow for very gradual cooling
to take place. This provides time for formation of the single-crystalline superlattices that are the thermodynamically favored
product. Additionally, controlled crystallization also occurs when protein-DNA conjugates are mixed with spherical nucleic
acid (SNA)–nanoparticle (NP) conjugates. The method by Brodin et al. opens up opportunities to control and program protein
assembly; enzyme-based chemical nanoreactors might be now within our reach.
Brodin et al. (2015). Proc. Natl. Acad. Sci. USA. Published March 23, 2015. http://dx.doi.org/10.1073/pnas.1503533112Inorganic Polyphosphate Meets Protein
If you think about proteins as polypeptide chainsmade of twenty different amino acids, you are getting only a part of the story.
The chemical diversity of amino acid side chains is significantly expanded via a numerous, and ever growing, list of posttrans-
lational modifications (PTMs). Azevedo et al. now add one more PTM to the list—polyphosphorylation. The authors follow up
on an interesting discrepancy between in vivo and in vitro observations about the effect of a nonenzymatic PTM, pyrophos-
phorylation (pyroP). PyroP is a result of a phosphate transfer from inositol pyrophosphate diphosphoinositol pentakisphos-
phate (IP7) to a phosphoserine. Its targets, including yeast Nsr1, a nuclear protein with a role in rRNA biogenesis, display a
significant gel mobility shift on NuPAGE in vivo when IP7 is present. However, pyroP did not recapitulate this effect in vitro.
Azevedo et al. first show that the extent of the gel mobility shift seen for Nsr1 is linked to the level of IP7 in yeast cells, and
more IP7 results in a bigger smear. The levels of inositol pyrophosphates are also linked to levels of inorganic polyphosphate
(polyP), and Azevedo et al. present evidence that it is the polyP levels that are directly correlated with Nsr1 mobility in vivo and
in vitro. Further examination of polyP modification demonstrated that it is nonenzymatic; that it targets a specific area in Nsr1,
the polyacidic serine (S) and lysine (K)-rich (PASK) cluster; and that polyP attaches to lysines, unlike pyroP, which is present on
serines. This is found to be the case for both Nsr1 and topoisomerase 1 (Top1), an interaction partner of Nsr1 and anotherChemistry & Biology 22, April 23, 2015 ª2015 Elsevier Ltd All rights reserved 429
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interaction and Top1 activity. It is worth highlighting that polyphosphorylation is independent of pyrophosphorylation and that
the relation between them comes only from the fact that IP7 is metabolically associated with inorganic polyP. It will be inter-
esting to see how our understanding of polyP develops and whether polyP turns out to be a general PTM.
Azevedo et al. (2015). Mol. Cell 58, 71–82. http://dx.doi.org/10.1016/j.molcel.2015.02.010Dissecting Selectivity Profile of BH3 Mimics
Drug discovery and development is an expensive undertaking, and costs are these days often measured in billions of US dol-
lars. One of the major contributors to this price tag is the fact that more than 90% of drug candidates fail clinical trials, mostly
because of problems with efficacy and side-effects causing dose-limiting toxicities. Navitoclax (ABT-263), for example, is an
experimental anticancer drug with good efficacy against lymphoid malignancies. Unfortunately, it also causes a decrease in
platelet count, thrombocytopenia, which limits the maximum dose of navitoclax that can be administered. In another clinical
scenario, when navitoclax is used in combination with a chemotherapeutic, docetaxel, as a treatment for solid tumors, it leads
to bone marrow suppression, resulting in febrile neutropenia.
Mechanistically, navitoclax is a BH3 mimetic, which means that it binds to antiapoptotic members of Bcl-2 family, such
as Bcl-2, Bcl-XL, and Bcl-W (although to Bcl-W with much weaker affinity), and prevents them from engaging BH3 motifs
of proapoptotic members of the family, thus allowing apoptosis to occur. The open question regarding the observed side
effects is their mechanistic origin and whether they are caused by inhibition of Bcl-2 or Bcl-XL. Leverson et al. now use the
Bcl-2 selective inhibitor venetoclax (ABT-199/GDC-0199) and the newly described Bcl-XL selective inhibitors A-1155463
and A-1331852 to address this question. By selectively inhibiting either Bcl-2 or Bcl-XL in vitro and in vivo, Leverson et al.
show that this set of small molecules can be used to separate the effects of Bcl-2 andBcl-XL inhibition. This leads to the obser-
vation that the beneficial effects of navitoclax when combined with taxanes in solid tumors are attributable to its inhibitionAlthough perhaps not as epic as the
struggle between good and evil depicted
in John Milton’s ‘‘Paradise Lost,’’ the
study of the process bywhich pluripotent
stem cells (PSCs) exit pluripotency
continues to offer new twists to our
understanding of what happens as PSCs
undergo spontaneous differentiation.
Moussaieff et al. describe the unusual
metabolic feature of early differentiation.
Image source: John Milton [Public
domain], via Wikimedia Commons and
EC65.M6427P.1667aa, Houghton Library,
Harvard University.
430 Chemistry & Biology 22, April 23, 2015of BCL-XL, while neutropenia is due to Bcl-2 inhibition. On the flip side, the beneficial
effects of navitoclax in hematologic cancers come from Bcl-2 inhibition and the
toxicity (thrombocytopenia) from BCL-XL inhibition. Thus, further development of
selective BH3 mimics seems worth pursuing as a way to minimize side effects and
improve efficacy.
Leverson et al. (2015). Sci. Transl. Med. 7, 279ra40. http://dx.doi.org/10.1126/
scitranslmed.aaa4642Losing Pluripotency: Metabolites Paint a Picture
Embryonic stem cells are notorious for their ability to self-renew and maintain the
state of pluripotency. Equally important for ensuring normal development, tissue
formation, and organogenesis is the ability of pluripotent stem cells (PSCs) to exit
this state and spontaneously differentiate into one of the three germ layers in the
embryo. En route to the differentiated state, PSCs undergo numerous changes
and transitions, including well-documented changes in their metabolomes; however,
at this point it is not clear what happens in the earliest time points of spontaneous
differentiation and whether metabolic changes precede and potentially cue in later
steps in the process.
Moussaieff et al. now focus their analysis on the first 48 hr of the spontaneous
differentiation and observe that although changes to gene expression were only
mild, there were significant changes to 44 metabolites and a clear metabolic
transition in cultured I3 and I4 human embryonic stem cells (hESCs). Out of the
44 metabolites, Moussaieff et al. zoom in on lactate and acetate, which are present
in high levels in I4 and I3 hESC and decrease as the differentiation progresses. The
authors show that PSCs exhibit increased production of acetyl-CoA via glycolysis
and that this production is significantly slowed down in the early phase of differenti-
ation. The addition of acetate, an acetyl-CoA precursor, delayed the loss of pluripo-
tency, and higher levels of acetate and the glycolytic acetyl-CoA lead to an increase
of histone acetylation in PSCs. Moussaieff et al. use diverse pieces of evidence to
paint an interesting picture of Ac-CoA as a crucial player in maintaining pluripotency
and offer an intriguing proposal that pluripotency is under metabolic regulation and
that glycolysis is in the crux of it all.
Moussaieff et al. (2015). Cell Met. 3, 392–402. http://dx.doi.org/10.1016/j.cmet.2015.
02.002
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